ClinicalTrials.gg
TerminatedNCT04893083Updated Oct 30, 2023

A Non-interventional Study for the Collection of Biospecimens From Patients With Parkinson's Disease

An observational study in Parkinson Disease, sponsored by Neuron23 Inc.. Terminated at 8 sites in 4 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2023-10-30.

Sponsored by Neuron23 Inc. · Observational

How we know

Why this study was terminated
Business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
65
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.

Enrollment
205th of 379
65 · median 78
Started
2021
with 103 others
Observational
381 of 1,650
75 open now
Registered
1,168th of 1,650
by date

Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 205th largest by enrollment of the 379 observational ones that give a count, is one of 104 that started in 2021, is one of 381 observational ones, and was the 1,168th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

300 more — sign in →

All 305 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,650 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

This study aims to collect, analyze and preserve biospecimens from patients with or without LRRK2-associated Parkinson's Disease for the purpose of discovering and developing new treatments and novel biomarkers.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Parkinson's patients will be recruited across this multi-center, global clinical study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥40
  • Clinical diagnosis of Parkinson's disease meeting United Kingdom Brain Bank criteria and modified Hoehn and Yahr Stage I, II, or III;
  • Willing to undergo genetic testing for neurologic genotyping panel; -If being treated for Parkinson's disease, must have been on a stable dose of anti- Parkinson's disease medications for a minimum of 30 days prior to Day 1;
  • If taking statins, fibrates, antipsychotic or anticonvulsant medications at Day 1, must have been on a stable dose for a minimum of 30 days, and are not likely to require a change in dosage for the remainder of the study;

Exclusion criteria

Exclusion Criteria:

  • Any major medical illness or unstable medical condition within 6 months of screening that, in the opinion of the Investigator or Sponsor, may interfere with the subject's ability to comply with study procedures or abide by study restrictions.
  • Diagnosis of a significant central nervous system disease other than Parkinson's disease(eg, Huntington's disease, frontotemporal dementia, multi-infarct dementia, normal pressure hydrocephalus, multiple system atrophy, progressive supranuclear palsy, drug- induced parkinsonism, Alzheimer's disease)
  • History of stroke;
  • History of epilepsy or seizure disorder other than febrile seizures as a child, or any seizure or unexpected loss of consciousness (eg, syncope) within 6 months prior to Day 1;
  • History of traumatic brain injury with residual neurological deficit; -If taking anti-Parkinson's disease medication(s)and are likely to require a change in anti- Parkinson's disease medication(s) during the study;
  • Known active infectious disease or active infections within 30 days prior to Day 1;
  • Any vaccination within 21 days prior to Day 1;
  • Currently taking, or planning to take, anti-coagulant medications or antiplatelet medications during the study;
  • Allergy to Lidocaine (xylocaine) or its derivatives or any other LP ;
  • Any other condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the subject's risk by participating in the study; -Any systemic taken within 14 days prior to Day 1 or non-steroidal anti- inflammatory drugs taken within 4 days prior to Day 1;
  • Received blood products within 30 days prior to Day 1;
  • Donated blood within 30 days prior to Day 1.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
65 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • LRRK2 Mutant PD

    Patients with a G2019S mutation

  • LRRK2 Wild Type PD Low burden

    Patients with a low burden of genetic modifiers

  • LRRK2 Wild Type High burden

    Patients with a high burden of genetic modifiers

06

What researchers measure

Primary outcomes

  1. Genetic Marker

    Test for LRRK2 mutations in Parkinson disease patients; identifying patients with potential genetic modifiers

    Time frame: 1 day

07

Study locations

8 sites
  • Rocky Mountain Movement Disorders Center
    Englewood, Colorado 80113, United States
  • Quest Research Institute
    Farmington Hills, Michigan 48334, United States
  • Evergreen Health
    Kirkland, Washington 98034, United States
  • Universite Laval
    Québec City, Quebec, Canada
  • McGill University
    Montréal, Canada
  • Assistance Publique - Hospitaux de Paris
    Paris, France
  • Sheba Tel HaShomer
    Ramat Gan, Israel
  • Tel Aviv Medical Center
    Tel Aviv, Israel
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Jun 2023, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2021
First posted
May 19, 2021
StartActual
Jun 28, 2021
Primary completionActual
Jun 30, 2023
CompletionActual
Sep 22, 2023
Last update
Oct 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04893083
Lead sponsor
Neuron23 Inc.
Responsible party
Sponsor
First posted
May 19, 2021
Start date
Jun 28, 2021
Primary completion
Jun 30, 2023
Completion
Sep 22, 2023
Last update
Oct 30, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion